Companies /Healthcare
Integra Lifesciences Holdings Corp
NASDAQ: IART Medical Devices
$13.98
▼ $0.42 (−2.92%) today
Markets closed · 9:16pm ET

Integra LifeSciences (IART) Q3 2026 Earnings

Reported Oct 21, 2026, 6:15am ET · SEC source
$0.59
Beat +5.51%
EPS · est. $0.56 Adjusted
$411.2M
Miss −0.22%
Revenue · est. $412.1M
5 quarters
Consecutive EPS beats

How Did IART Stock React to Q3 2026 Earnings?

% change · around the report
−10%−5%0Oct 20Oct 28report 6:15am ETearnings−0.2%−7.6%
−10%−5%0Oct 20Oct 28earnings−0.2%−7.6%
IART −7.6%S&P 500 −0.2%
−10%−5%0Oct 20Oct 28report 6:15am ETearnings−0.3%−7.6%
−10%−5%0Oct 20Oct 28earnings−0.3%−7.6%
IART −7.6%NASDAQ −0.3%
−11.18%
Day of report
+4.10%
Next session
+3.38%
One week

Did IART Beat Earnings? Q3 2026 Results

Yes. Integra LifeSciences reported Q3 2026 earnings of $0.59 a share on Oct 21, 2026, beating the $0.56 consensus estimate by 5.5%. Revenue was $411.2M against a $412.1M estimate.

Integra LifeSciences delivered a mixed third quarter for fiscal 2026, beating on the bottom line while falling just short on revenue, extending its streak of adjusted EPS beats to four consecutive quarters. The company posted adjusted EPS of $0.59, topping the $0.56 consensus estimate by 5.51% and improving from $0.54 a year ago, even as revenue of $411.18 million trailed the $412.10 million consensus by 0.22%, rising 2.3% year over year. The quarter's central story was the flood damage at Integra's Cincinnati manufacturing facility, which clipped approximately $7.00 million from the top line and weighed on adjusted gross margin, which contracted to 61.1% from 62.9% in the prior year. Neurosurgery was a bright spot within the Specialty Surgery segment, growing 6.5% organically, while Tissue Reconstruction declined 2.2%. Looking ahead, the company guided full-year 2026 revenue to $1.63 billion to $1.65 billion with adjusted EPS of $2.30 to $2.40, a forecast that already accounts for the Cincinnati recovery timeline and incremental interest costs from the company's October debt refinancing. The stock has drawn scrutiny from investors' attorneys following the guidance reduction tied to the facility disruption.

Key Takeaways
  • Neurosurgery organic growth of 6.5% driven by CereLink, Certas Plus, Bactiseal, DuraSeal, and cranial perforator recovery
  • Strong operating cash flow of $96.0 million in Q3 2026
  • Approximately $7 million revenue impact from Cincinnati facility flood damage
  • Tissue Reconstruction decline of 2.2% due to softness in MicroMatrix and Integra Skin
  • ENT decline largely driven by low-single digit decline in sinus balloons

“Our third quarter performance reflected mixed results across our portfolio, with stronger performance in Specialty Surgery partially offset by a $7 million impact from the Cincinnati disruption and softer-than-expected results in Tissue Reconstruction. We delivered results within our guidance ranges, generated strong cash flow, reduced leverage, and subsequently completed our debt refinancing.”

Integra LifeSciences CEO, on the earnings call

What Is Integra LifeSciences's Outlook?

For Q4 2026, the company expects reported revenues of $413 million to $433 million (reported decline of -5.2% to -0.5%, organic decline of -5.1% to -0.4%) and adjusted EPS of $0.61 to $0.71. For full year 2026, the company expects revenues of $1.634 billion to $1.654 billion (reported growth of -0.1% to 1.2%, organic growth of -0.3% to 0.9%), adjusted EPS of $2.30 to $2.40, and operating cash flow of approximately $190 million to $200 million. The outlook reflects the expected revenue impact of the Cincinnati disruption, updated expectations for Tissue Reconstruction, business interruption insurance recoveries, and incremental interest expense from the refinancing. The company expects its effective interest rate increase to be near the high end of a 100- to 200-basis-point range.

IART YoY Financials

Q3 2026 vs Q3 2025 · SEC filings Q3 2025 Q3 2026
$0$200.0M$400.0M$402.1M$411.2MRevenue$226.1M$209.9MGross Profit$40.3M$18.9MOperating Income$3.1M$14.9MNet Income
$0$200.0M$400.0MRevenueGross ProfitOperating IncomeNet Income
IART income statement, Q3 2026 versus Q3 2025
Metric Q3 2026 Q3 2025 Year over year
Revenue $411.2M $402.1M +2.3%
Gross Profit $209.9M $226.1M −7.2%
Operating Income $18.9M $40.3M −53.1%
Net Income $14.9M $3.1M +374.8%

IART Revenue by Segment

Neurosurgery$214.1M+6.2%
Wound Reconstruction and Care$81.5M−2.9%
Instruments$49.7M−1.0%
ENT$40.4M−1.2%
Private Label
Corporate Partnerships$25.5M+0.2%

Figures from SEC filings and company reports. Not investment advice.